Jun 29, 2026 07:00AM
Sep 5, 2025 08:00AM
Nov 15, 2024 08:00AM
Mar 20, 2024 08:00AM
Feb 28, 2024 01:00AM
Jul 10, 2023 09:00AM
May 10, 2023 09:00AM Idorsia Pharmaceuticals Announces Support for a Clinical Trial being Conducted by the U.S. Department of Defense Evaluating QUVIVIQ (daridorexant) as Potential Therapy for Treatment of Posttraumatic S
Apr 4, 2023 09:05AM
Dec 20, 2022 01:00AM
Dec 12, 2022 01:00AM
Nov 15, 2022 07:32PM
Nov 10, 2022 08:30AM
Jul 26, 2022 01:00AM
May 23, 2022 01:00AM Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension
May 2, 2022 08:00AM
Feb 8, 2022 01:00AM
Jan 20, 2022 07:30AM
Jan 10, 2022 08:30AM
Jan 10, 2022 01:00AM
Jan 10, 2022 12:55AM
Jul 27, 2021 01:01AM Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company
Jun 28, 2021 01:00AM
Jun 9, 2021 01:00AM
Apr 22, 2021 01:00AM
Mar 10, 2021 01:00AM
Jan 11, 2021 01:00AM
Aug 28, 2020 02:30PM
Aug 13, 2020 01:00AM Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020
Jul 23, 2020 01:00AM
Jul 16, 2020 01:00AM
Jul 6, 2020 01:00AM
May 11, 2020 05:03PM
May 11, 2020 04:01PM
Jan 10, 2020 01:00AM
Nov 19, 2019 07:00AM REMINDER: Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.
Nov 19, 2019 01:00AM

326,270 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All